← All trials
NCT06507059
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 19, 2024
- Primary completion
- Jul 1, 2025
- Completion date
- Dec 31, 2026
- First posted
- Jul 18, 2024
- Last posted
- Aug 23, 2024
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chang Gung UniversityLead sponsor
- Taoyuan General HospitalCollaborator
- Chang Gung UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.